TITLE

Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond

AUTHOR(S)
Moher, David; Altman, Douglas G.; Schulz, Kenneth F.; Elbourne, Diana R.
PUB. DATE
August 2004
SOURCE
CMAJ: Canadian Medical Association Journal;8/17/2004, Vol. 171 Issue 4, p349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the challenges and opportunities for improving the quality of reporting randomized controlled trials. Bases for improvements in the quality of reporting of clinical research; Concerns about the state and quality of clinical research; Initiatives undertaken to improve the quality of reporting clinical research.
ACCESSION #
14044248

 

Related Articles

  • The Two Period Crossover Design in Medical Research. Woods, John R.; Williams, James G.; Tavel, Morton // Annals of Internal Medicine;4/1/89, Vol. 110 Issue 7, p560 

    Deals with the two-period crossover design in medical research. Features of the crossover design; Advantages of the crossover design; Deficiencies of the crossover design; Clinical sources of confounding in crossover designs.

  • In Pursuit of Enlightenment. Bowers, Linda // Applied Clinical Trials;Aug2011, Vol. 20 Issue 8, p46 

    The article offers the author's perspective regarding the theme of clinical study teams in clinical trials. The author recalls that during a clinical outsourcing conference in London, England she realized that most of the study teams desire to have greater visibility and insights into clinical...

  • Empirical Power and Sample Size Calculations for Cluster-Randomized and Cluster-Randomized Crossover Studies Reich, Nicholas G.; Myers, Jessica A.; Obeng, Daniel; Milstone, Aaron M.; Perl, Trish M. // PLoS Clinical Trials;Apr2012, Vol. 7 Issue 4, p1 

    In recent years, the number of studies using a cluster-randomized design has grown dramatically. In addition, the cluster-randomized crossover design has been touted as a methodological advance that can increase efficiency of cluster-randomized studies in certain situations. While the...

  • The delay in sharing research data is costing lives. Sommer, Josh // Nature Medicine;Jul2010, Vol. 16 Issue 7, p744 

    In this article, the author reflects on release of life-saving research. The author points out that scientists need enough money and resources to initiate and publish results of their clinical trials and other studies on life science. The author asserts that financial support is highly needed to...

  • Update on Russia Trials.  // Applied Clinical Trials;Jul2008, Vol. 17 Issue 7, p22 

    The article discusses the report of Russian contract research organization (CRO) Synergy Research Group on the present condition of the clinical trials market in Russia. According to the report, the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation...

  • Liability issues for data monitoring committee members. DeMets, David L; Fleming, Thomas R; Rockhold, Frank; Massie, Barry; Merchant, Thomas; Meisel, Alan; Mishkin, Barbara; Wittes, Janet; Stump, David; Califf, Robert // Clinical Trials;2004, Vol. 1 Issue 6, p525 

    In randomized clinical trials, a data monitoring committee (DMC) is often appointed to review interim data to determine whether there is early convincing evidence of intervention benefit, lack of benefit or harm to study participants. Because DMCs bear serious responsibility for participant...

  • Clinical Trials in New Europe. DOIG, AL // Bio-IT World;Jan2009, Vol. 8 Issue 1, p13 

    The article presents an outlook for clinical trials in New Europe for 2009. The collapse of the Soviet Union is cited as one of the major factors which contributed to the emergence of new opportunity for clinical trials in Europe. An overview of the report from Insight Pharma Reports entitled...

  • Relevance of the clinical impact factor. Blitzkow, Gilson; Estrela, Carlos // Dental Press Endodontics;Jan-Apr2015, Vol. 5 Issue 1, p5 

    The author discusses the importance of systematic literature reviews to analyze clinical impact factors and select accurate and appropriate articles.

  • Nicardipine in the Treatment of Raynaud's Phenomenon: A Randomized Double-Blind Trial. Kahan, André; Amor, Bernard; Menkès, Charles J.; Weber, Simon; Guérin, Francois; Degeorges, Michel // Angiology;Apr1987, Vol. 38 Issue 4, p333 

    The efficacy of the calcium-channel blocker nicardipine in the treatment of Raynaud's phenomenon was assessed in a prospective, double-blind, randomized, crossover trial in 20 patients. Each patient received nicardipine 20 mg or placebo three times a day for two weeks and then was crossed over...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics